#Orum Therapeutics, Inc. plummeted by over 33% in after-hours trading after BMS halted development of the blood cancer candidate “ORM-6151” and returned the rights. In contrast, OSCOTEC Inc.(039200)rose 8.59% on news of the launch of a special committee to pursue making Genosco a wholly-owned subsidiary. #AriBio also rose 5.59% on news that, together with AriBio Holdings, it would invest a total of 18 billion won in ARIBIOLAB and become its largest shareholder.
Orum Therapeutics, Inc.’ ‘ORM-6151’ Returned by BMS… After-hours Trading Plummets 33%Bristol-Myers Squibb (BMS) has halted development of “ORM-6151,” a blood cancer treatment candidate licensed from Orum Therapeutics, Inc., and returned the rights. As this was the only candidate in Orum Therapeutics, Inc.’s pipeline to have entered clinical trials, the news sent shockwaves through the investment community.
According to Orum Therapeutics, Inc., BMS decided not to proceed with further development after reviewing the clinical data for ORM-6151. Consequently, the rights to ORM-6151 held by BMS under the technology transfer agreement signed in 2023 have been returned to Orum Therapeutics, Inc.
News of the return of ORM-6151 caused the stock price to fluctuate significantly. According to KG Zeroin MP DOCTOR (formerly Marketpoint) that day, in after-hours trading at 6:02 p.m., Orum Therapeutics, Inc.’s stock price traded at 35,500 won—a 33.52% drop from the regular session’s closing price of 53,400 won.
BMS has been conducting Phase 1 clinical trials of ORM-6151 in the U.S., Europe, and Canada. ORM-6151 is an antibody-drug conjugate (DAC) candidate that was being developed for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It was being evaluated in clinical trials not only as a monotherapy but also as a three-drug regimen in combination with azacitidine and venetoclax.
According to the clinical trial registration information, the primary endpoint for this trial was expected to be reached in February 2027. However, following BMS’s decision to halt development, the trial is now set to be terminated earlier than originally planned.
As a result of the contract termination, the subsequent milestone payments that Orum Therapeutics, Inc. would have received have also been forfeited. According to the company, the total value of the remaining milestone payments was $80 million (110.7 billion won). However, the $100 million (138.4 billion won) in upfront payments received at the time of the contract will not be returned.
In a regulatory filing, Orum Therapeutics, Inc. stated, “BMS’s obligation to pay additional milestone payments has been extinguished,” and announced its intention to focus its efforts on the research and development of future pipeline candidates using its proprietary DAC platform.
This return is also expected to pose a burden in terms of validating Orum Therapeutics, Inc.’s platform. ORM-6151 was a key program in which the company’s DAC technology was being evaluated in clinical trials led by a global pharmaceutical company. There had also been expectations that BMS’s direct conduct of a multinational clinical trial would confirm the clinical potential of the DAC platform.
However, with the discontinuation of ORM-6151’s development, Orum Therapeutics, Inc.’s clinical-stage pipeline is once again empty. The company is preparing “ORM-1153,” a follow-up DAC candidate, as its new clinical pipeline and plans to initiate clinical trials by the end of next year.
Previously, Orum Therapeutics, Inc. had also halted clinical development of “ORM-5029,” another DAC candidate it had been developing in-house. ORM-5029 is a candidate that combines a GSPT1 degrader with an antibody targeting HER2. Development was halted after serious adverse events and a fatality occurred during a Phase 1 clinical trial in 2024.
The market’s sensitive reaction is believed to stem from the fact that ORM-6151 served not only as a standalone pipeline but also as a vehicle for clinically validating Orum Therapeutics, Inc.’s DAC platform. With the development of both ORM-5029 and ORM-6151 now halted, the company’s ability to advance subsequent candidates—such as ORM-1153—into clinical trials and secure data is expected to become a key factor in re-establishing the competitiveness of its platform.
OSCOTEC Inc. Soars on Launch of Special Committeeto Make
Genosco a Wholly-Owned SubsidiaryOSCOTEC Inc.(039200)
surgedon news that it had formed
a special committeeto make Genosco
a wholly-owned subsidiary.
On that day, OSCOTEC Inc. closed at 37,300 won, up 2,950 won (8.59%) from the previous trading day.
OSCOTEC Inc. announced on the 17th that it had held a board meeting on the 15th and finalized the formation of a special committee regarding the acquisition of Genosco as a wholly-owned subsidiary. The special committee will independently examine potential conflicts of interest that may arise during the acquisition of the remaining shares and deliberate on major decisions.
OSCOTEC Inc. is the original developer of “Lecraza” (generic name: lazertinib), a domestically developed anticancer drug that has received approval from the U.S. Food and Drug Administration (FDA). It holds a 59.31% stake in Genosco, which is based in the United States.
The plan to make Genosco a wholly-owned subsidiary emerged as an alternative during discussions with shareholders after the initially proposed standalone IPO of Genosco was suspended.
The special committee will first establish criteria and procedures for selecting an external valuation firm and will then review key issues related to the acquisition of the remaining stake in Genosco in stages. To ensure objectivity, the company is also pursuing a plan to obtain valuations from multiple external firms. Independent Director Kim Kyu-sik, former chairman of the Korea Corporate Governance Forum, has been appointed as the committee chair.
Based on the valuation results, OSCOTEC Inc. plans to negotiate the terms for acquiring the remaining shares with Genosco’s minority shareholders and then finalize the specific transaction structure and financing plan. The company is also considering attracting strategic investors (SIs) or financial investors (FIs), taking into account existing shareholder value and financial burdens.
OSCOTEC Inc. officials stated, “The specific method of financing has not yet been decided,” adding, “If we attract external investors, we will comprehensively evaluate whether they will contribute to long-term corporate value and strengthen our capabilities in global new drug development and business development.”
Aribio to Become Largest Shareholder of ARIBIOLAB… Stock Price Rises on 18 Billion Won Investment#Aribio
,together with Aribio Holdings, is investing
18 billion wonin
ARIBIOLABto strengthen the group’s biotech research and development (R&D) framework. With Aribio becoming the largest shareholder, collaboration in the vaccine, immunology, and mRNA sectors is expected to expand significantly.
The stock price rose on the day this news was announced. AriBio closed at 4,250 won, up 225 won (5.59%) from the previous trading day.
According to an electronic disclosure by the Financial Supervisory Service that day, AriBio and AriBio Holdings will invest 15 billion won and 3 billion won, respectively, in a third-party private placement being conducted by ARIBIOLAB.
Upon completion of the capital increase, AriBio will secure a 15.9% stake in ARIBIOLAB, becoming its largest shareholder. AriBio Holdings will become the second-largest shareholder with a 14.1% stake. The combined stake of the two companies will total 30%.
The K-Bio Deal Summit 2026, held under the theme “K-Bio: Solutions for Global Success Through Innovation,” was organized to examine the success strategies of companies leading the global market and to share insights on the growth direction of the domestic biotech industry and investment opportunities.
This investment is expected to mark the beginning of a full-scale consolidation of the group’s new drug development capabilities. AriBio has secured global clinical development experience and a research network while conducting a global Phase 3 clinical trial for the oral Alzheimer’s disease treatment “AR1001.”
ARIBIOLAB is focusing on the development of vaccines and immunotherapies based on its proprietary immune-enhancing platform. The shingles vaccine “CVI-VZV-001,” which utilizes the immune-enhancing platforms “L-pampo” and “Lipo-pam,” is currently undergoing a Phase 2 clinical trial in Korea.
“CTRNA-001,” a next-generation immuno-oncology drug utilizing mRNA-lipid nanoparticle (LNP) technology, has also been selected as a project under the National New Drug Development Program, and development of the candidate compound is underway.
In particular, the two companies recently began joint development of an Alzheimer’s vaccine. By expanding their collaboration beyond existing oral Alzheimer’s treatments to include vaccines, they aim to create synergies in the field of neurodegenerative diseases.
This investment is interpreted as a move to strengthen ARIBIOLAB’s strategic role within the group, rather than merely providing financial support. With AriBio securing the position of largest shareholder and AriBio Holdings also becoming a major shareholder, the direction to cultivate ARIBIOLAB as a core pillar of vaccine, immunology, and mRNA R&D has become clearer.
Going forward, the combination of AriBio’s new drug development experience gained through the global clinical trials of AR1001 and ARIBIOLAB’s vaccine and immunology platforms is expected to expand the interconnections within the group’s pipeline, ranging from Alzheimer’s treatments to vaccines and immuno-oncology drugs.
